Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cor Therapeutics Inc. (CORR) -- Ignore unavailable to you. Want to Upgrade?

To: LLCF who wrote (415)	4/26/1999 11:56:00 AM
From: aknahow	Read Replies (1) \| Respond to of 712

Ditto on the thanks. That information makes more sense to me than saying the quarters sales were higher than what was expected.

To: LLCF who wrote (415)	4/26/1999 12:24:00 PM
From: LLCF	Read Replies (1) \| Respond to of 712

<<The company has increased estimates for Integrilin sales to $65 - $70 million this year, $175 - $200 million for 2000, and $300 - $350 million for 2001.> <Total sales of INTEGRILIN, as reported to COR by Schering-Plough, were $11,300,000 for the quarter ended March 31, 1999, as compared to $8,400,000 for the quarter ended December 31, 1998, a 35% increase. > <Contract revenues for the quarter ended March 31, 1999 included $5,668,000 of copromotion revenue related to the sales of INTEGRILIN by Schering-Plough> The actual compared to total year estimates show quite large growth assumptions as you can see... If this really pans out you've got a great little company here. dAK